This lecture was part of a Cardio Diabetes Master Class 'Contemporary issues in T2DM & cardiovascular risk: Review of latest insights for optimizing patient management' held on November 5-6 2016 in Seoul Korea

Educational information

The educational objectives of this Cardio Diabetes Master Class were:

• To explore mechanisms and common pathways underlying the development of cardiovascular disease and diabetes
• To review and discuss the importance of glucose management and the rationale for early intervention strategies in patients with diabetes
• To discuss the role of anti-diabetic therapy, in particular the use of DPP4 inhibitors and TZD’s, in a risk-based intervention strategy that targets glucose control and cardiovascular risk factors
• To discuss therapies that work through other insulin-related mechanisms, including insulin resistance, in order to reduce the incidence of cardiovascular events; especially in high-risk patient populations with a history of an ACS event and multiple risk factors
• To evaluate the current guidelines for the management of patients with diabetes and high CV risk, and identify potential novel targets for therapy in this high-risk patient group
• To discuss current and future strategies for practical management and interventions to prevent cardiovascular events in multirisk patients

CME accreditation

The Cardio Diabetes Master Class is accredited by the European Board for Accreditation in Cardiology (EBAC) for 9 CME credit hours

Disclosures

prof Sanjay Rajagopalan, MD, FACC, FAHA s Chief, Cardiovascular Medicine, Herman Hellerstein Chair of Cardiovascular Research Director, Cardiovascular Research Institute - Professor of Medicine, Case Western Reserve School of Medicine, Cleveland, OH, USA

Funding

The master class is supported by an unrestricted educational grant provided by Takeda Pharmaceuticals

View slides of this lecture